For the quarter ending 2025-09-30, CAI had $34,295K increase in cash & cash equivalents over the period. $55,330K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 24,325 | -174,370 |
| Depreciation and amortization | 4,870 | 13,454 |
| Stock-based compensation expense | 13,655 | 42,984 |
| Non-cash operating lease expense | 1,387 | 2,936 |
| Amortization of debt discounts | 2,463 | 9,700 |
| Changes in fair value of financial instruments | -2,081 | -50,203 |
| Loss on debt extinguishment | 0 | -17,930 |
| Other | 443 | -1,231 |
| Accounts receivable | -24,192 | -37,040 |
| Supplies | 8,523 | 2,621 |
| Prepaid expenses and other current assets | 2,540 | 2,265 |
| Other assets | 660 | -334 |
| Accounts payable | 729 | -1,925 |
| Accrued expenses and other liabilities | 889 | -18,681 |
| Net cash provided by (used in) operating activities | 62,425 | -24,050 |
| Maturities of marketable securities | 0 | 0 |
| Purchases of property and equipment | 7,095 | 4,075 |
| Net cash provided by (used in) investing activities | -7,095 | -4,075 |
| Payments made on finance lease obligations | 23 | 44 |
| Proceeds from exercise of stock options | 1,151 | 2,624 |
| Payment of taxes withheld from net settlement of exercised options and vested rsus | 16,560 | 1,658 |
| Payment of deferred offering costs | 5,665 | 2,045 |
| Proceeds from the 2023 term loan, net of issuance costs | 0 | 0 |
| Purchase of treasury stock | 0 | 22 |
| Proceeds from issuance of preferred stock, net of issuance costs-Series EPreferred Stock | 0 | 87,637 |
| Proceeds from issuance of preferred stock, net of issuance costs-Series FPreferred Stock | 0 | 33,601 |
| Issuance of the 2025 convertible notes, net of issuance costs | 0 | 27,865 |
| Issuance of the 2025 warrants | 0 | 10,270 |
| Payments of 2023 term loan amendment fee | 0 | 4,000 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 | 528,459 |
| Net cash provided by financing activities | -21,097 | 682,687 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 62 | 97 |
| Net increase in cash, cash equivalents, and restricted cash | 34,295 | 654,659 |
| Cash and cash equivalents at beginning of period | 68,028 | - |
| Cash and cash equivalents at end of period | 756,982 | - |
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)